Net Cash Provided by Operating Activities 354,485 331,865
---------- ----------
Cash Flow From Investing Activities:
Capital expenditures (including instruments
placed with or leased to customers) (128,674) (183,632)
Acquisition of Mayne Pharma, net of
cash acquired (1,961,285) -
Settlements of foreign currency contracts (55,701) -
Proceeds from dispositions of product rights 13,771 -
Other, net (1,263) 1,845
---------- ----------
Net Cash Used in Investing Activities (2,133,152) (181,787)
---------- ----------
Cash Flow From Financing Activities:
Issuance of long-term debt, net of
fees paid 3,336,198 -
Repayment of long-term debt (1,700,124) (111)
Other borrowings, net (343) 1,955
Payment to Abbott Laboratories for
international assets - (124,251)
Common stock repurchased - (299,766)
Excess tax benefit from stock-based
compensation arrangements 865 3,373
Proceeds from stock options exercised 40,464 39,576
---------- ----------
Net Cash Provided by (Used in)
Financing Activities 1,677,060 (379,224)
---------- -------
'/>"/>
| SOURCE Hospira, Inc. Copyright©2007 PR Newswire. All rights reserved |